Literature DB >> 23820308

Desensitization of human CRF2(a) receptor signaling governed by agonist potency and βarrestin2 recruitment.

Richard L Hauger1, J Alberto Olivares-Reyes, Sandra Braun, Judith Hernandez-Aranda, Christine C Hudson, Eric Gutknecht, Frank M Dautzenberg, Robert H Oakley.   

Abstract

The primary goal was to determine agonist-specific regulation of CRF2(a) receptor function. Exposure of human retinoblastoma Y79 cells to selective (UCN2, UCN3 or stresscopins) and non-selective (UCN1 or sauvagine) agonists prominently desensitized CRF2(a) receptors in a rapid, concentration-dependent manner. A considerably slower rate and smaller magnitude of desensitization developed in response to the weak agonist CRF. CRF1 receptor desensitization stimulated by CRF, cortagine or stressin1-A had no effect on CRF2(a) receptor cyclic AMP signaling. Conversely, desensitization of CRF2(a) receptors by UCN2 or UCN3 did not cross-desensitize Gs-coupled CRF1 receptor signaling. In transfected HEK293 cells, activation of CRF2(a) receptors by UCN2, UCN3 or CRF resulted in receptor phosphorylation and internalization proportional to agonist potency. Neither protein kinase A nor casein kinases mediated CRF2(a) receptor phosphorylation or desensitization. Exposure of HEK293 or U2OS cells to UCN2 or UCN3 (100nM) produced strong βarrestin2 translocation and colocalization with membrane CRF2(a) receptors while CRF (1μM) generated only weak βarrestin2 recruitment. βarrestin2 did not internalize with the receptor, however, indicating that transient CRF2(a) receptor-arrestin complexes dissociate at or near the cell membrane. Since deletion of the βarrestin2 gene upregulated Gs-coupled CRF2(a) receptor signaling in MEF cells, a βarrestin2 mechanism restrains Gs-coupled CRF2(a) receptor signaling activated by urocortins. We further conclude that the rate and extent of homologous CRF2(a) receptor desensitization are governed by agonist-specific mechanisms affecting GRK phosphorylation, βarrestin2 recruitment, and internalization thereby producing unique signal transduction profiles that differentially affect the stress response.
© 2013.

Entities:  

Keywords:  CK1; CK2; CRF receptor type 1; CRF receptor type 2(a); CRF(1) receptor; CRF(2(a)) receptor; Corticotropin releasing factor receptor (CRF); G protein-coupled receptor; GPCR; GPCR kinase; GRK; K44A; PKA; PKC; SCP; SRP; Urocortin 1 (UCN1); Urocortin 2 (UCN2); Urocortin 3 (UCN3); casein kinase 1; casein kinase 2; dynamin dominant negative mutant; protein kinase A; protein kinase C; stresscopin; stresscopin-related peptide; βarrestin2

Mesh:

Substances:

Year:  2013        PMID: 23820308      PMCID: PMC3924877          DOI: 10.1016/j.regpep.2013.06.009

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  49 in total

1.  Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-beta-arrestin complexes after receptor endocytosis*.

Authors:  R H Oakley; S A Laporte; J A Holt; L S Barak; M G Caron
Journal:  J Biol Chem       Date:  2001-03-09       Impact factor: 5.157

2.  Are we beta-ARKing up the wrong tree? Casein kinase 1 alpha provides an additional pathway for GPCR phosphorylation.

Authors:  Andrew B Tobin
Journal:  Trends Pharmacol Sci       Date:  2002-07       Impact factor: 14.819

3.  Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor.

Authors:  S Y Hsu; A J Hsueh
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

4.  GRK3 mediates desensitization of CRF1 receptors: a potential mechanism regulating stress adaptation.

Authors:  F M Dautzenberg; S Braun; R L Hauger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-04       Impact factor: 3.619

5.  Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors.

Authors:  R H Oakley; S A Laporte; J A Holt; M G Caron; L S Barak
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

6.  Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor.

Authors:  K Lewis; C Li; M H Perrin; A Blount; K Kunitake; C Donaldson; J Vaughan; T M Reyes; J Gulyas; W Fischer; L Bilezikjian; J Rivier; P E Sawchenko; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

7.  Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors.

Authors:  T M Reyes; K Lewis; M H Perrin; K S Kunitake; J Vaughan; C A Arias; J B Hogenesch; J Gulyas; J Rivier; W W Vale; P E Sawchenko
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

8.  Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse.

Authors:  K Van Pett; V Viau; J C Bittencourt; R K Chan; H Y Li; C Arias; G S Prins; M Perrin; W Vale; P E Sawchenko
Journal:  J Comp Neurol       Date:  2000-12-11       Impact factor: 3.215

Review 9.  The CRF peptide family and their receptors: yet more partners discovered.

Authors:  Frank M Dautzenberg; Richard L Hauger
Journal:  Trends Pharmacol Sci       Date:  2002-02       Impact factor: 14.819

10.  beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking.

Authors:  T A Kohout; F S Lin; S J Perry; D A Conner; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

View more
  4 in total

Review 1.  The CRF System as a Therapeutic Target for Neuropsychiatric Disorders.

Authors:  Jeff Sanders; Charles Nemeroff
Journal:  Trends Pharmacol Sci       Date:  2016-10-04       Impact factor: 14.819

Review 2.  Endocrinology and the brain: corticotropin-releasing hormone signaling.

Authors:  Carolina Inda; Natalia G Armando; Paula A Dos Santos Claro; Susana Silberstein
Journal:  Endocr Connect       Date:  2017-07-14       Impact factor: 3.335

3.  Acute Corticotropin-Releasing Factor Receptor Type 2 Agonism Results in Sustained Symptom Improvement in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Gerard Pereira; Hunter Gillies; Sanjay Chanda; Michael Corbett; Suzanne D Vernon; Tina Milani; Lucinda Bateman
Journal:  Front Syst Neurosci       Date:  2021-09-01

4.  Xiao Yao San Improves Depressive-Like Behavior in Rats through Modulation of β-Arrestin 2-Mediated Pathways in Hippocampus.

Authors:  Xiaoxia Zhu; Oudong Xia; Weili Han; Meng Shao; Linlin Jing; Qin Fan; Yuanliang Liu; Jianxin Diao; Zhiping Lv; Xuegang Sun
Journal:  Evid Based Complement Alternat Med       Date:  2014-07-07       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.